UNIGE document Scientific Article
previous document  unige:78726  next document
add to browser collection

Cannabinoïdes médicaux dans les douleurs chroniques : aspects pharmacologiques

Published in Revue médicale suisse. 2015, vol. 11, no. 480, p. 1390,1392-4
Abstract In Switzerland, medical cannabinoids can be prescribed under compassionate use after special authorization in justified indications such as refractory pain. Evidence of efficacy in pain is limited and the clinical benefit seems to be modest. Their drug-drug interactions (DDI) profile is poorly documented. Cytochromes P450 (CYP) 2C9 and 3A4 are involved in the metabolism of tetrahydrocannabinol and cannabidiol, which implies possible DDI with CYP450 inhibitor and inducer, such as anticonvulsivants and HIV protease inhibitors, which may be prescribed in patients with neuropathic pain.
Keywords Cannabinoids/pharmacology/therapeutic useChronic Pain/drug therapyDrug InteractionsHumansMedical Marijuana/pharmacology/therapeutic useSwitzerlandTreatment Outcome
PMID: 26267945
Full text
Article (Published version) (478 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research groups Groupe Desmeules Jules (pharmacologie/toxicologie) (567)
Médecine de l'addiction (129)
(ISO format)
ING LORENZINI, Kuntheavy et al. Cannabinoïdes médicaux dans les douleurs chroniques : aspects pharmacologiques. In: Revue médicale suisse, 2015, vol. 11, n° 480, p. 1390,1392-4. https://archive-ouverte.unige.ch/unige:78726

558 hits



Deposited on : 2015-12-16

Export document
Format :
Citation style :